npj Vaccines banner

Challenges and developments in universal vaccine design against SARS-CoV-2 variants

  • Fangxin Zhao
  • Xiaodong Zai
  • Wei Chen
Review Article


  • Please note we strongly recommend to our authors writing about SARS-CoV-2 that they follow WHO approved nomenclature for variant strains. We recommend the Pango nomenclature, but GISAID and Nexstrain are also approved.

  • npj Vaccines has a 2-year impact factor of 9.399 (2021), article downloads of 1,255,808 (2021) and 6 days from submission to the first editorial decision (2021).

  • Springer Nature is committed to recognizing the valuable and critical role performed by peer reviewers. We fully support verifying and crediting your review activity directly to ORCID.


Nature Careers